The Genitourinary Market Outlook to 2016
Business Insights
August 31, 2011 7 Pages - SKU: RET6647613
|
|
This report covers the major indications in the genitourinary market outlook: urinary incontinence and overactive bladder, benign prostatic hyperplasia, erectile dysfunction, hormonal contraception, and infertility. Leading brands, companies, and pipeline products are examined along with market and epidemiology forecasts.
Assess the potential of leading pipeline products in the genitourinary market.
Compare the franchises of leading companies and understand how these will perform to 2016.
Learn which therapy areas present the greatest unmet need.
Analyze the regional performance of the genitourinary market.
Identify the indications which have the greatest patient potential.
There are significant unmet needs in urinary incontinence, erectile dysfunction, and benign prostatic hyperplasia. Urinary incontinence and overactive bladder have the greatest number of products in development.
Traditionally Pfizer has dominated the urinary incontinence market. However, as Detrol/Detrol LA’s patent expiry nears, the company is losing its leading position to Astellas which aims to make urology products one of its key growth drivers in the next decade and is forecast to achieve total sales of $1.7 billion in 2016.
The launch of generic Viagra (sildenafil) will strongly impact the erectile dysfunction market and sales will decrease to $3.0 billion in 2016. All markets, with the exception of Japan, will shrink in value and the US in particular will drop from $2.2 billion in 2010 to $1.0 billion in 2016.
Where are the greatest unmet needs in the geniturinary market?
Which therapy areas have the strongest pipelines and which developmental products have the greatest potential?
Which indications will show growth in patient numbers to 2016?
What are the relative positions of the leading companies in the genitourinary market by indication?
How will each of the seven major markets perform in terms of genitourinary sales?
Please note: this is delivered as a Zip file.
|
- About the author
- Disclaimer
- EXECUTIVE SUMMARY
- Overview of the genitourinary market
- Urinary incontinence and overactive bladder
- Benign prostatic hyperplasia
- Erectile dysfunction
- Hormonal contraception
- Infertility
- Overview of the genitourinary market
- Summary
- Introduction
- Market overview and forecasts
- Market definitions
- Market size and forecasts
- Market analysis by geography
- Leading brands
- Company dynamics
- Pipeline overview
- Urinary incontinence and overactive bladder are the strongest pipelines
- Unmet needs
- Urinary incontinence and overactive bladder
- Benign prostatic hyperplasia
- Erectile dysfunction
- Hormonal contraceptives
- Infertility
- Urinary Incontinence and overactive bladder
- Summary
- Introduction
- Overview
- Diagnosis, treatment and management
- Treatment and management
- Epidemiology
- Forecast epidemiology
- Market analysis
- Sales and forecasts
- Leading brands
- Market position of the key players in urinary incontinence and overactive bladder
- Astellas
- Pfizer
- Urinary incontinence and overactive bladder pipeline analysis
- Leading drugs in development for urinary incontinence and overactive bladder
- Betanis (mirabegron) - Astellas
- Botox (botulinum toxin A) - Allergan
- Anturol (oxybutynin gel) - Antares
- Benign prostatic hyperplasia
- Summary
- Introduction
- Overview
- Diagnosis, treatment and management
- Diagnosis
- Treatment and management
- Epidemiology
- Forecast epidemiology
- Market analysis
- Sales and forecasts
- Leading brands
- Market position of the key players in benign prostatic hyperplasia
- GlaxoSmithKline
- Benign prostatic hyperplasia pipeline analysis
- Leading drugs in development for benign prostatic hyperplasia
- Tadalafil - Eli Lilly
- NX1207 - Nymox
- Erectile dysfunction
- Summary
- Introduction
- Overview
- Diagnosis, treatment and management
- Diagnosis
- Treatment and management
- Epidemiology
- Forecast epidemiology
- Market analysis
- Sales and forecasts
- Leading brands
- Market position of the key players in erectile dysfunction
- Pfizer
- Eli Lilly
- Erectile dysfunction pipeline analysis
- Leading drugs in development for urinary incontinence and overactive bladder
- Avanafil - Vivus
- Hormonal contraception
- Summary
- Introduction
- Overview
- Diagnosis, treatment and management
- Treatment and management
- Epidemiology
- Forecast epidemiology
- Market analysis
- Sales forecasts
- Leading brands
- Market position of the key players in hormonal contraception
- Bayer
- Hormonal contraceptives pipeline analysis
- Leading drugs in development for hormonal contraception
- AG20015 (levonorgestrel and ethinyl estradiol) - Agile
- Zoely/Nomac/E2 (nomegestrol acetate + natural estrogen) - Teva/Merck & Co.
- Infertility
- Summary
- Introduction
- Overview
- Diagnosis, treatment and management
- Diagnosis
- Treatment and management
- Epidemiology
- Forecast epidemiology
- Market analysis
- Sales and forecasts
- Leading brands
- Market position of the key players in infertility
- Merck KGaA
- Merck & Co.
- Infertility pipeline analysis
- Leading drugs in development for infertility
- DR2011 (progesterone vaginal ring) - Teva
- Appendix
- Scope
- Key genitorurinary indications covered in this report
- Methodology
- Market forecast
- Epidemiology forecast
- Glossary/Abbreviations
- Bibliography/References
- Websites
Share this report
Other tasks Related Markets Men's Health Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
